Ascentage Pharma names Yiqing Chen as chief financial officer
29 November 2021 -

Biopharmaceutical company Ascentage Pharma (6855.HK), a developer of novel therapies for cancers, chronic hepatitis B (CHB) and age-related diseases, revealed on Monday that it has appointed Yiqing Chen as chief financial officer (CFO).

Chen will report directly to Dr Dajun Yang, Ascentage Pharma's chairman and chief executive officer (CEO).

The company added that as a member of its senior executive team, Chen will focus his work on the capital market, financial management, investor relations, to drive Ascentage Pharma's long-term and sustained growth in the capital market.

Previously, Chen was vice CFO and general manager of Investor Relations and Capital Deployment at Fosun Pharma and also served as deputy general manager and CFO at BGI Genomics.

Earlier, Chen spent eight years at accounting firms and in project management at securities companies, including Citi Orient Securities, Orient Securities and the Shanghai branch of Ernst & Young.